• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: THERAKOS CELLEX PHOTOPHERESIS SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

THERAKOS CELLEX PHOTOPHERESIS SYSTEM Back to Search Results
Model Number NOT APPLICABLE
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Itching Sensation (1943); Chest Tightness/Pressure (2463); No Code Available (3191)
Event Date 04/29/2019
Event Type  Injury  
Manufacturer Narrative
The system was used for treatment.This case is reportable as a mdr due to the medical intervention of the benadryl that was provided to the patient.Since this event is associated with the treatment, this mdr will be against the instrument.From the instrument perspective, there was no known instrument malfunction and no instrument issue was alleged by the customer.No service was requested by the customer for this adverse event.The instrument has been located at the customer's site since 25-jan-2010.The customer has their own biomedical engineer who performs all of the service for this instrument.Trends were reviewed for complaint categories, itchy, face/neck flushing, and chest tightness.No trends were detected for these complaint categories.The assessment is based on information available at the time of the investigation.Complaints are monitored through tracking and trending.If a trend is detected, further investigation will be conducted.Adverse event terms: itching, no code available: face/neck flushing, chest tightness/pressure.(b)(4).
 
Event Description
The customer reported that an extracorporeal photopheresis (ecp) patient experienced itchiness, face/neck flushing, and chest tightness during a treatment procedure.The customer stated that the patient was experiencing a heparin reaction during their ecp treatment procedure.The customer reported that at about 190ml of whole blood processed, the patient complained of itchiness in their neck area.The customer stated that they then stopped the patient's ecp treatment procedure, waited a few minutes and then resumed the patient's treatment procedure.The customer reported that within a few minutes after re-starting the patient's treatment procedure, the patient complained of itchiness again.The customer stated that they stopped the patient's treatment procedure once again, waited a few minutes and then re-started the patient's treatment procedure.The customer reported that at about 400ml of whole blood processed, the patient complained of both an itchy neck and hands as well as chest tightness.The customer stated that the patient's face had also become red.The customer reported that they then aborted the patient's treatment procedure with no blood returned to the patient.The customer stated that they administered both 500ml of normal saline and 50cc of benadryl to the patient.The customer reported that the patient was now in stable condition.The customer stated that the patient had no complaints prior to starting their treatment procedure.The customer reported that this was the patient's 51st ecp treatment procedure.The customer stated that the patient comes in for an ecp treatment procedure once every two weeks.The customer reported that when they first began treating this patient, they were using acda as the anticoagulant for the patient's ecp treatment procedures.However, the customer stated that when the patient could no longer tolerate the acda, they switched to heparin as the anticoagulant on (b)(6) 2018.The customer reported that this was the first time that the patient has had a heparin reaction.The customer stated that the dose of heparin that was used for the patient's treatment procedure was 10,000 units in 500ml normal saline.The customer reported that the heparin was prepared for them by their pharmacy.The customer stated that the heparin ratio that was used for this treatment procedure was 8:1 due to the patient's high platelet count.No product was returned for investigation.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CELLEX PHOTOPHERESIS SYSTEM
Type of Device
CELLEX PHOTOPHERESIS SYSTEM
Manufacturer (Section D)
THERAKOS
bedminster NJ
Manufacturer (Section G)
MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
college business & tech park
cruiserath road
blanchardstown, D15 T X2V
EI   D15 TX2V
Manufacturer Contact
megan vernak
1425 us route 206
bedminster, NJ 07921
MDR Report Key8652288
MDR Text Key146475013
Report Number2523595-2019-00062
Device Sequence Number1
Product Code LNR
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P860003
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Reporter Occupation Nurse
Type of Report Initial
Report Date 05/29/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Device Operator Health Professional
Device Model NumberNOT APPLICABLE
Device Catalogue NumberCELLEX
Device Lot NumberNOT APPLICABLE
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 04/29/2019
Initial Date FDA Received05/29/2019
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured12/14/2009
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Reuse
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age68 YR
Patient Weight63
-
-